Trading volume for Vericel Corproation was 1,033K in the last trading session. Volume was up 113.67% over the stocks average daily volume.
Short traders are more bullish on shares of Vericel Corproation of late considering the change in short interest. The firm had a fall in short interest of -12.48% as of October 13, 2017 from the last reporting period. Short shares fell from 1,131,154 to 989,949 over that timeframe. The short-interest ratio decreased to 1.0 and the percentage of shorted shares was 0.03% on October 13.
These funds have shifted positions in (VCEL). Ladenburg Thalmann Financial Services Inc. downsized its position by shedding 1 shares a decrease of 50.0% as of 09/30/2017. Ladenburg Thalmann Financial Services Inc. claims 1 shares valued at $0. The value of the position overall is down by nan%. Royal Bank Of Canada divested its ownership by selling 2 shares a decrease of 33.3%. Royal Bank Of Canada now controls 4 shares with a value of $0. The total value of its holdings decreased nan%.
As of quarter end State Street Corp had bought a total of 5,800 shares growing its position 31.7%. The value in dollars went from $60,000 to $144,000 a change of $84,000 quarter over quarter. As of the end of the quarter Kopp Investment Advisors LLC had acquired 30,662 shares growing its stake by 56.7%. The value of the total investment in Vericel Corproation increased from $178,000 to $508,000 a change of 185.4% quarter to quarter.
Equity analyst BTIG Research released a research note on VCEL and giving a rating of “Buy” and a price target of $6.00. On August 10 Piper Jaffray Companies held the stock rating at “Buy” targeting a price of $7.00.
September 7 investment analysts at BTIG Research kept the stock rating at “Buy” projecting a price of $6.00. On October 2 analysts at BTIG Research released research on VCEL stating a rating of “Buy” and establishing a price target of $6.00.
The company is trading down by 0.52% since yesterday’s close of 4.3. The P/E ratio is currently N/A and the market cap of the company is 140.42M. As of the last earnings report the EPS was $-0.88 with 34.85M shares presently outstanding.
Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc., launched on March 24, 1989, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns approximately 30% of total body surface area (TBSA)..